


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Canceled)
2. (Currently amended) A Compound's compound of the general formula

Formula (I)



(I)

or a prodrug, a stereoisomer or a pharmacologically acceptable salt thereof,

wherein:

R and R₁ have the meanings as given in claim 1, R and R₁ independently represent a phenyl, naphthyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl or triazinyl group, which groups are optionally substituted with 1-4 substituents X, which can be the same or different, and are chosen from branched and unbranched (C₁₋₃)-alkyl and alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- and dialkyl (C₁₋₂)-amino, mono- and dialkyl (C₁₋₂)-amido, (C₁₋₃)-

alkoxycarbonyl, trifluoromethylsulfonyl, sulfamoyl, (C₁₋₃)-alkylsulfonyl, carboxyl, cyano, carbamoyl, (C₁₋₃)-dialkylaminosulfonyl, (C₁₋₃)-monoalkylamino-sulfonyl and acetyl groups;

R₂ represents a hydrogen atom or a branched or unbranched C₁₋₈ alkyl group;


R₃ represents branched or unbranched, C₂₋₈ alkoxy, C₃₋₈ cycloalkyl, C₅₋₁₀ bicycloalkyl, C₆₋₁₀ tricycloalkyl, C₄₋₈ alkenyl, C₅₋₈ cycloalkenyl, which groups may optionally contain one or more heteroatoms chosen from the group (O, N, S) O, N, and S, which ~~groups may optionally be~~ heteroatoms are optionally substituted with a hydroxy group or 1-3 fluoro atoms, or R₃ represents a C₃₋₈ trifluoroalkyl or C₂₋₈ fluoroalkyl group, or R₃ represents a benzyl or phenethyl group, which aromatic rings ~~may be~~ are optionally substituted with 1-4 substituents X, wherein X has the meaning as given in ~~claim 1~~ above, or R₃ represents a 3-pyridyl, 4-pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl or thienyl group, which heteroaromatic rings ~~may be~~ are optionally substituted with ~~1-2~~ 1 or 2 substituents X, wherein X has the meaning as given in ~~claim 1~~ above, or

R₃ represents a group NR₄R₅, wherein

R₄ and R₅, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic moiety having 4 to 10 ring atoms, which heterocyclic moiety contains one or two heteroatoms chosen from the ~~group N, O or S~~ O, N, and S, which heteroatoms can be the same or different, ~~which~~ and wherein the heterocyclic moiety may be is optionally substituted with a branched or unbranched C₁₋₃ alkyl, hydroxy or trifluoromethyl group or a fluoro atom, or

R₂ and R₃, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic ~~group~~ moiety having 4 to 10 ring atoms, which heterocyclic ~~group~~ moiety contains one or two heteroatoms chosen from ~~the group N, O or S, O, N, and S,~~ O, N, and S, which heteroatoms can be the same or different, ~~which and wherein the~~ heterocyclic moiety ~~may be~~ is optionally substituted with a branched or unbranched C₁₋₃ alkyl, hydroxy, piperidinyl or trifluoromethyl group or a fluoro atom, with the proviso that this heterocyclic moiety is not an unsubstituted piperidinyl or unsubstituted morpholinyl group or 2,2,6,6-tetraalkylpiperidinyl group, ~~and prodrugs, stereoisomers and salts thereof.~~

3. (Currently amended) ~~The Compounds~~ A compound of the ~~general formula~~
Formula (I)



(I)


or a prodrug, a stereoisomer or pharmacologically acceptable salt thereof,

wherein:

R and R₁ independently represent a phenyl, naphtyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl or triazinyl group, which groups are substituted with 1-4 substituents X, wherein X ~~has the meaning as given in claim 1~~, which can be the same or different, and are chosen from branched and unbranched (C₁₋₃)-alkyl and alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- and dialkyl (C₁₋₂)-amino, mono- and dialkyl (C₁₋₂)-amido, (C₁₋₃)-alkoxycarbonyl, trifluoromethylsulfonyl, sulfamoyl, (C₁₋₃)-alkylsulfonyl, carboxyl, cyano, carbamoyl, (C₁₋₃)-dialkylaminosulfonyl, (C₁₋₃)-monoalkylamino-sulfonyl and acetyl groups; and

R₂ and R₃ have the meanings as given in claim 2, ~~and prodrugs, stereoisomers and salts thereof.~~

4. (Currently amended) A Compound compound of the general formula (I) as claimed in claim 2 and having Formula (I), or a prodrug, a stereoisomer or a pharmacologically acceptable salt thereof, wherein:



(This line indicates structure is to be deleted.)

(I)

R and R₁ each independently represent a phenyl group ~~which phenyl groups are~~ substituted with 1-4 substituents which ~~can be~~ are the same or different, and are chosen from ~~the group~~ methyl, methoxy, halogen, trifluoromethyl ~~or~~ and cyano, or R and R₁ each independently represent a phenyl, thienyl or pyridyl group, which phenyl group is optionally substituted with 1-4 substituents, which ~~can be~~ are the same or different, ~~from the group~~ and are chosen from methyl, methoxy, halogen, trifluoromethyl ~~or~~ and cyano;

~~R₂ has the meaning as given in claim 2~~ R₂ represents a hydrogen atom or a branched or unbranched C₁₋₈ alkyl group;

R₃ represents a group NR₄R₅, wherein

R₄ and R₅ together, with the nitrogen atom to which they are bonded, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic moiety having 4 to 10 ring atoms, ~~which~~ wherein the heterocyclic group contains one or two heteroatoms chosen from ~~the group N, O or S,~~ O, N, and S, which heteroatoms can be the same or different, ~~which~~ and wherein the heterocyclic moiety ~~may be~~ is optionally substituted with a branched or unbranched C₁₋₃ alkyl, hydroxy or trifluoromethyl group or a fluoro atom, ~~and prodrugs, stereoisomers and salts thereof.~~

5. (Currently amended) ~~Pharmaceutical compositions containing a pharmacologically active amount of at least one compound of one of the claims 1-4 as an active ingredient~~ A pharmaceutical composition comprising at least one pharmacologically active compound of Formula (I) according to claim 2, or a prodrug, a stereoisomer or a pharmacologically acceptable salt thereof.

6. (Currently amended) ~~Use of a compound of one of the claims 1-4 for the preparation of a pharmaceutical composition for the treatment of disorders involving A~~


method for preparing a pharmaceutical composition for treatment of at least one disorder involving CB₁ cannabinoid neurotransmission comprising combining at least one pharmacologically active compound of Formula (I) according to claim 2, or a prodrug, a stereoisomer or a pharmacologically acceptable salt thereof, with at least one pharmaceutically acceptable auxiliary substance.

7. (Currently amended) ~~Use as in claim 6 characterized in that said disorders are: psychosis, anxiety, depression, attention deficits, memory disorders, cognitive disorders, appetite disorders, obesity, addiction, appetence, drug dependence, neurodegenerative disorders, dementia, dystonia, muscle spasticity, tremor, epilepsy, multiple sclerosis, traumatic brain injury, stroke, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, cerebral apoplexy, craniocerebral trauma, stroke, spinal cord injury, neuroinflammatory disorders, plaque sclerosis, viral encephalitis, demyelination related disorders, as well as for the treatment of pain disorders, including neuropathic pain disorders, septic shock, glaucoma, diabetes, cancer, emesis, nausea, gastrointestinal disorders, gastric ulcers, diarrhoea and cardiovascular disorders.~~

The method according to claim 6, wherein the at least one disorder involving CB₁ cannabinoid neurotransmission is chosen from psychosis, anxiety, depression, attention deficits, memory disorders, cognitive disorders, appetite disorders, obesity, addiction, appetence, drug dependence, neurodegenerative disorders, dementia, dystonia, muscle spasticity, tremor, epilepsy, multiple sclerosis, traumatic brain injury, stroke, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, cerebral apoplexy, craniocerebral trauma, stroke, spinal cord injury,

neuroinflammatory disorders, plaque sclerosis, viral encephalitis, demyelination
related disorders, as well as for the treatment of pain disorders, including neuropathic
pain disorders, septic shock, glaucoma, diabetes, cancer, emesis, nausea,
gastrointestinal disorders, gastric ulcers, diarrhea and cardiovascular disorders.

8. (New) A method for treating at least one disorder involving CB₁ cannabinoid neurotransmission comprising administering a pharmaceutical composition comprising at least one pharmacologically active compound of Formula (I),



(I)

or a prodrug, a stereoisomer or a pharmacologically acceptable salt thereof, and at least one pharmaceutically acceptable auxiliary substance to a patient in need of said treatment, wherein:

R and R₁ independently represent a phenyl, naphthyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl or triazinyl group, which groups are optionally substituted with 1-4 substituents X, which can be the same or different, and are chosen from branched and unbranched (C₁₋₃)-alkyl and alkoxy, hydroxy, halogen, trifluoromethyl,

trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- and dialkyl (C₁₋₂)-amino, mono- and dialkyl (C₁₋₂)-amido, (C₁₋₃)-alkoxycarbonyl, trifluoromethylsulfonyl, sulfamoyl, (C₁₋₃)-alkylsulfonyl, carboxyl, cyano, carbamoyl, (C₁₋₃)-dialkylaminosulfonyl, (C₁₋₃)-monoalkylamino-sulfonyl and acetyl groups;

R₂ represents a hydrogen atom or a branched or unbranched C₁₋₈ alkyl or C₁₋₈ cycloalkyl-alkyl group or a phenyl, benzyl or phenethyl group, which aromatic rings are optionally substituted with 1-4 substituents X, wherein X has the meaning indicated above, or R₂ represents a pyridyl or thienyl group;

R₃ represents branched or unbranched C₁₋₈ alkyl, C₁₋₈ alkoxy, C₃₋₈ cycloalkyl, C₅₋₁₀ bicycloalkyl, C₆₋₁₀ tricycloalkyl, C₃₋₈ alkenyl, C₅₋₈ cycloalkenyl, which groups optionally contain one or more heteroatoms chosen from O, N, and S, which groups are optionally substituted with a hydroxy group, an ethynyl group or 1-3 fluoro atoms, or R₃ represents a phenyl, benzyl or phenethyl group, which aromatic rings are optionally substituted with 1-4 substituents X, wherein X has the meaning indicated above, or R₃ represents a pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl or thienyl group, wherein the heteroaromatic rings are optionally substituted with 1-2 substituents X, wherein X has the meaning indicated above, or R₃ represents a group NR₄R₅ wherein

R₄ and R₅, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic moiety having 4 to 10 ring atoms, which heterocyclic moiety contains one or two heteroatoms chosen from N, O or S, which heteroatoms are the same or different, and wherein the heterocyclic moiety is optionally substituted with a branched or unbranched C₁₋₃ alkyl, hydroxy or trifluoromethyl group or a fluoro atom, or

R₂ and R₃, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic moiety having 4 to 10 ring atoms, wherein the heterocyclic moiety contains one or two heteroatoms chosen from N, O and S, which heteroatoms can be the same or different, and wherein the heterocyclic moiety is optionally substituted with a branched or unbranched C₁₋₃ alkyl, hydroxy, piperidinyl or trifluoromethyl group or a fluoro atom.

9. (New) The method according to claim 8, wherein the at least one disorder involving CB₁ cannabinoid neurotransmission is chosen from psychosis, anxiety, depression, attention deficits, memory disorders, cognitive disorders, appetite disorders, obesity, addiction, appetite, drug dependence, neurodegenerative disorders, dementia, dystonia, muscle spasticity, tremor, epilepsy, multiple sclerosis, traumatic brain injury, stroke, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, cerebral apoplexy, craniocerebral trauma, stroke, spinal cord injury, neuroinflammatory disorders, plaque sclerosis, viral encephalitis, demyelination related disorders, as well as for the treatment of pain disorders, including neuropathic pain disorders, septic shock, glaucoma, diabetes, cancer, emesis, nausea, gastrointestinal disorders, gastric ulcers, diarrhea and cardiovascular disorders.